KAUST, NEOM Unveil World's Largest Coral Restoration Project

KCRI is the world's largest coral restoration project, aiming to restore reefs worldwide. SPA
KCRI is the world's largest coral restoration project, aiming to restore reefs worldwide. SPA
TT

KAUST, NEOM Unveil World's Largest Coral Restoration Project

KCRI is the world's largest coral restoration project, aiming to restore reefs worldwide. SPA
KCRI is the world's largest coral restoration project, aiming to restore reefs worldwide. SPA

King Abdullah University of Science and Technology (KAUST), in collaboration with NEOM, has started working on the first nursery of the KAUST Coral Restoration Initiative (KCRI), a statement from KAUST said on Thursday.

According to the statement, KCRI is the world's largest coral restoration project, aiming to restore reefs worldwide. The primary nursery is already operational, and a second facility is being developed, both located in the Red Sea.

KCRI is funded by KAUST, a world-class graduate research university in Saudi Arabia, which was recently ranked as the number one Arab University by Times Higher Education.

The newly built nursery, on the coast of NEOM in northwest Saudi Arabia, will transform coral restoration efforts with a production capacity of 40,000 corals annually. Functioning as a pioneering pilot facility, researchers will leverage it as the blueprint for large-scale coral restoration initiatives.

Most importantly, this facility serves as a precursor to a more ambitious project: the world's largest and most advanced land-based coral nursery. This nursery, located at the same site, is an advanced coral nursery that will boast a ten-fold larger capacity to nurture 400,000 corals annually. With construction quickly progressing, the project is anticipated to reach completion by December 2025.

Home to 25% of known marine species despite covering less than 1% of the sea floor, coral reefs are the bedrock of numerous marine ecosystems. "This is one reason why scientists are so concerned about the rising rate of mass bleaching events, with experts estimating up to 90% of global coral reefs will experience severe heat stress on an annually by 2050," the statement said. With the frequency of such events on the rise, solutions for coral recovery will be "crucial for a healthy ocean.”

In alignment with Saudi Vision 2030 and its efforts to bolster marine conservation, this major initiative leverages KAUST's research into marine ecosystems and serves as a platform for trialing innovative restoration methods. Set on a 100-hectare site; the initiative will deploy 2 million coral fragments, marking a significant step in conservation efforts.

According to the statement, KCRI aligns with KAUST's overarching strategy, showcasing its dedication to catalyzing positive societal and global outcomes.

Beyond environmental restoration, the project offers educational benefits, further reinforcing its alignment with the broader strategic goals outlined in Vision 2030.

"Recent events provide a stark reminder of the global crisis that coral reefs face. Our ambition is, therefore, to pioneer a pathway to upscale from the current labor-intensive restoration efforts to industrial-scale processes required to reverse the current rate of coral reef degradation,” said KAUST President Prof. Tony Chan.

“As a significant output of KAUST's new strategy, the university is contributing the world-leading expertise of our faculty, who are working on technologies to bring this vision to fruition."

NEOM's CEO, Nadhmi Al-Nasr, said the initiative demonstrates NEOM's dedication to sustainability and finding innovative solutions for global environmental challenges.

NEOM, as a "pioneer in sustainable development" recognizes the importance of reviving coral reefs in partnership with KAUST. Through their longstanding collaboration, they aim to raise awareness about the significance of coral reefs as crucial marine environmental systems and emphasize the need to preserve them for future generations.



Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
TT

Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights

Women’s heart disease risks and their need to start taking preventive medications should be evaluated when they are in their 30s rather than well after menopause as is now the practice, said researchers who published a study on Saturday.

Presenting the findings at the European Society of Cardiology annual meeting in London, they said the study showed for the first time that simple blood tests make it possible to estimate a woman’s risk of cardiovascular disease over the next three decades.

"This is good for patients first and foremost, but it is also important information for (manufacturers of) cholesterol lowering drugs, anti-inflammatory drugs, and lipoprotein(a)lowering drugs - the implications for therapy are broad," said study leader Dr. Paul Ridker of Brigham and Women’s Hospital in Boston, Reuters reported.

Current guidelines “suggest to physicians that women should generally not be considered for preventive therapies until their 60s and 70s. These new data... clearly demonstrate that our guidelines need to change,” Ridker said. “We must move beyond discussions of 5 or 10 year risk."

The 27,939 participants in the long-term Women’s Health Initiative study had blood tests between 1992 and 1995 for low density lipoprotein cholesterol (LDL-C or “bad cholesterol”), which are already a part of routine care.

They also had tests for high-sensitivity C-reactive protein (hsCRP) - a marker of blood vessel inflammation - and lipoprotein(a), a genetically determined type of fat.

Compared to risks in women with the lowest levels of each marker, risks for major cardiovascular events like heart attacks or strokes over the next 30 years were 36% higher in women with the highest levels of LDL-C, 70% higher in women with the highest levels of hsCRP, and 33% higher in those with the highest levels of lipoprotein(a).

Women in whom all three markers were in the highest range were 2.6 times more likely to have a major cardiovascular event and 3.7 times more likely to have a stroke over the next three decades, according to a report of the study in The New England Journal of Medicine published to coincide with the presentation at the meeting.

“The three biomarkers are fully independent of each other and tell us about different biologic issues each individual woman faces,” Ridker said.

“The therapies we might use in response to an elevation in each biomarker are markedly different, and physicians can now specifically target the individual person’s biologic problem.”

While drugs that lower LDL-C and hsCRP are widely available - including statins and certain pills for high blood pressure and heart failure - drugs that reduce lipoprotein(a) levels are still in development by companies, including Novartis , Amgen , Eli Lilly and London-based Silence Therapeutics.

In some cases, lifestyle changes such as exercising and quitting smoking can be helpful.

Most of the women in the study were white Americans, but the findings would likely “have even greater impact among Black and Hispanic women for whom there is even a higher prevalence of undetected and untreated inflammation,” Ridker said.

“This is a global problem,” he added. “We need universal screening for hsCRP ... and for lipoprotein(a), just as we already have universal screening for cholesterol.”